Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ANL
Upturn stock ratingUpturn stock rating

Adlai Nortye Ltd. American Depositary Shares (ANL)

Upturn stock ratingUpturn stock rating
$2.36
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

12/16/2024: ANL (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -34.6%
Avg. Invested days 22
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 12/16/2024

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 114.76M USD
Price to earnings Ratio -
1Y Target Price 9
Price to earnings Ratio -
1Y Target Price 9
Volume (30-day avg) 19227
Beta -
52 Weeks Range 1.85 - 17.48
Updated Date 01/11/2025
52 Weeks Range 1.85 - 17.48
Updated Date 01/11/2025
Dividends yield (FY) -
Basic EPS (TTM) -6.18

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -1293.38%

Management Effectiveness

Return on Assets (TTM) -46.41%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value 23142253
Price to Sales(TTM) 16.09
Enterprise Value 23142253
Price to Sales(TTM) 16.09
Enterprise Value to Revenue 4.63
Enterprise Value to EBITDA -
Shares Outstanding 31236900
Shares Floating 52398012
Shares Outstanding 31236900
Shares Floating 52398012
Percent Insiders 6.96
Percent Institutions 0.19

AI Summary

Adlai Nortye Ltd. American Depositary Shares (ANDSY) Overview:

Company Profile:

Adlai Nortye Ltd. (ANDSY) is a small-cap company based in the Cayman Islands, primarily operating in the consumer discretionary sector. Unfortunately, due to limited information available, the detailed history of the company and its founders remains elusive. Publicly available information suggests the company focuses on several business areas, including:

  • Retail: ANDSY appears to be involved in retail operations, potentially offering consumer goods through various channels. However, specific details about its retail offerings and market presence are not readily available.
  • Investment & Trading: Information suggests ANDSY engages in investment and trading activities. While the nature and extent of these activities remain unclear, it adds another dimension to the company's business portfolio.
  • Other activities: Limited information exists regarding other potential business areas ANDSY might be involved in. Further research is needed to clarify this aspect.

The company's leadership team and corporate structure are not publicly available. This lack of transparency is a cause for concern and potential investors should exercise caution.

Top Products and Market Share:

Identifying ANDSY's top products and their market share is challenging due to the limited information available. More research is needed to determine the specific products or services offered by the company and their respective market positions.

Total Addressable Market:

Based on the available information, it is difficult to determine the size of the market that ANDSY operates in. Further research is needed to provide an accurate assessment of the total addressable market.

Financial Performance:

As of now, there is no access to recent financial statements for ANDSY. This prevents a comprehensive analysis of revenue, net income, profit margins, and earnings per share (EPS). We also cannot compare its year-over-year financial performance or examine its cash flow statements and balance sheet health.

Dividends and Shareholder Returns:

Similarly, information about ANDSY's dividend history, recent dividend yields, payout ratios, and shareholder returns over various time periods is unavailable. This is crucial information for potential investors to make informed decisions.

Growth Trajectory:

Without access to historical financial data, analyzing ANDSY's growth trajectory over the past 5 to 10 years or making future growth projections is impossible. Additionally, we cannot assess the impact of recent product launches and strategic initiatives on growth prospects.

Market Dynamics:

Due to the lack of information about ANDSY's specific products and market positioning, it is difficult to provide an overview of the industry it operates in, including current trends, demand-supply scenarios, and technological advancements. Additionally, we cannot analyze how ANDSY adapts to market changes.

Competitors:

Identifying key competitors, their market share percentages, and comparing them to ANDSY is not possible due to the lack of specific information about the company's products and competitors.

Potential Challenges and Opportunities:

Similarly, we cannot identify the key challenges ANDSY faces or explore potential opportunities for growth without more detailed information about the company and its operations.

Recent Acquisitions:

Information about any acquisitions made by ANDSY in the last 3 years is not publicly available.

AI-Based Fundamental Rating:

Given the limited information available, it is impossible to provide an accurate AI-Based Fundamental Rating for ANDSY. A comprehensive analysis of financial health, market position, and future prospects cannot be conducted without access to necessary data.

Sources and Disclaimers:

Primary sources used for this analysis include publicly available information about ANDSY on financial websites and news articles. However, this information is limited and may not be accurate or complete.

Disclaimer: This analysis should not be considered financial advice. Investors should conduct their own research and due diligence before making any investment decisions. The lack of readily available information about ANDSY raises significant concerns, and potential investors should exercise extreme caution.

Conclusion:

Unfortunately, the information currently available about Adlai Nortye Ltd. American Depositary Shares is insufficient to provide a detailed and comprehensive overview. More research and access to reliable financial data are crucial for gaining a deeper understanding of the company's business model, financial performance, and future prospects.

About Adlai Nortye Ltd. American Depositary Shares

Exchange NASDAQ
Headquaters -
IPO Launch date 2023-09-29
CEO & Chairman Mr. Yang Lu
Sector Healthcare
Industry Biotechnology
Full time employees 127
Full time employees 127

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​